Friday, July 13, 2018

Prodrug specialist reveals positive topline data for ADHD candidate - The Pharma Letter


The Pharma Letter

Prodrug specialist reveals positive topline data for ADHD candidate
The Pharma Letter
Iowa, USA-based specialty drugmaker KemPharm (Nasdaq: KMPH) says a key pivotal trial of its lead candidate, an investigational attention-deficit/hyperactivity disorder (ADHD) product, met the primary and secondary efficacy endpoint. The trial is ...
KemPharm Stock Down Despite Positive Data on ADHD CandidateZacks.com

all 2 news articles »

No comments:

Post a Comment